M. Flint Beal, M.D.

M. Beal

M. Flint Beal, MD is an internationally recognized authority on neurodegenerative disorders. He is the Anne Parrish Titzell Professor and Director of the Neurology service at the NewYork-Presbyterian Cornell Campus. Dr. Beal received his medical degree from the University of Virginia in 1976 and did his internship and first year residency in Medicine at New York-Cornell before completing his residency in Neurology at The Massachusetts General Hospital. He joined the neurology faculty at Harvard in 1983. Dr. Beal was Professor of Neurology at the Harvard Medical School and Chief of the Neurochemistry laboratory at Massachusetts General Hospital before moving to Cornell. Dr. Beal's research has focused on the mechanism of neuronal degeneration in Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and amyotrophic lateral sclerosis (ALS).

Dr. Beal is the author or co-author of more than 400 scientific articles and more than 125 books, book chapters and reviews. He serves on the editorial boards of seven journals, the Journal of Neurochemistry, the Annals of Neurology, Journal of Molecular Neuroscience, Experimental Neurology and Neurobiology of Disease. Dr. Beal's research has focused on the mechanism of neuronal degeneration in Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and amyotrophic lateral sclerosis (ALS). He has also been working on the development of novel neurochemical assays for assessing oxidative damage for use in clinical trials of new therapies for these disorders, as well as metabolomics for diagnosis.

Dr. Beal is a member of the Alpha Omega Alpha Medical Honorary Society and received the Derek Denny-Brown Neurological Scholar Award of the American Neurological Association. He has served on the Council and as Vice President of the American Neurological Association and on the Science Advisory Committees of the Hereditary Disease Foundation, Huntington's Disease Society of America, Parkinson's Disease Study Group, Parkinson' Disease Foundation, Bachman-Strauss Foundation, The ALS Association, and the American Health Assistance Foundation. Dr. Beal is also a member of the Institute of Medicine of the Namtional Academy of Sciences.

Selected Recent Papers (downloadable in Adobe Acrobat format*):

Energetics in the pathogenesis of neurodegenerative diseases

Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-795

Therapeutic effects of coenzyme Q10 and reduced COQ10 in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinsonism.  J Neurochem 2008; 104:1613-1621

Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008;131:389-96.

*If you don't have Acrobat Reader 3.0 or higher, you can download it from Adobe's website.


Recent Publications

Sugama S., Yang L, Cho BP, DeGiorgio L, Lorenzl S, Albers D, Beal MF. Age-related microglial activation in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003;964:288-294

Paul S, Bogdanov MB, Matson WR, Metakis L, Jacobs J, Beal MF. Urinary 8-hydroxy-2'-deoxyguanosine, a metabolite of oxidized DNA, is not elevated in HIV patients on combiantion antiretroviral therapy. Free Rad Res 2003, 37:499-502

Wu AS, Kiaei M, Aguirre N, Crow JP, Calingasan NY, Browne SE, Beal MF. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 2003:85:142-150

Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg S, Chirichigno J, Cudkowicz ME, Beal MF. Increased plasma levels of matrix metalloproteinase 9 in patients with Alzheimer's Disease. Neurochem Int 2003,43:191-196

Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's Disease transgenic mice. J Neurochem 2003,85:1359-1367

Zhang L, Ulug AM, Zimmerman RD, Lin M, Rubin M, Beal MF. The diagnostic utility of FLAIR imaging in clinically verified amyotrophic lateral sclerosis. J Magn Reson Imaging 2003,17:521-527

Gajewski CD, Lin MT, Cudkowicz ME, Beal MF, Manfredi G. Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in p0 cells. Exp Neurol 2003; 179:229-235

Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, Hilgenberg SL, Cudkowicz ME, Beal MF. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 2003, 207:71-76

Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's Disease. Ann Neurol 2003; 53:S39-S48

Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's Disease. Neuron 2003,37:899-909

Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal M.F., Albers DS. Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosc Res 2003;74:278-285

Klivenyi P., Ferrante R.J., Gardian G., Browne S., Pierre-Etienne C, Beal M.F. Increased survival and neuroprotective effects of BN-82451 in a transgenic mouse model of Huntington's disease. J Neurochem 2003;86:267-272

Lorenzl S., De Pasquale G., Segal A.Z., Beal, M.F. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke 2003;34,e37-e38

Klivenyi P., Gardian G., Calingasan N.Y., Yang L., Beal M.F. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's Disease. J Mol Neurosci 2003;21:191-198

Lin M. T. and Beal MF. The oxidative damage theory of aging. Clin Neurosci Res 2003; 2:305-315

Barberi T., Klivenyi P., Calingasan N.Y., Lee H., Kawamata H., Loonam K., Perrier A.L., Bruses J., Rubio M. E., Topf N., Tabar V., Harrison N. L., Beal M.F., Moore M. A., Studer L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol 2003; 21:1200-1207

Diano S., Matthews R.T., Patrylo P., Yang L., Beal M.F., Barnstable C.J., Horvath T.L.. Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology 2003;144:5014-5021

Andreassen OA., Ferrante RJ., Aamo TO., Beal MF., Jorgensen HA. Oral dyskinesias and histopathological alterations in susbstantia nigra after long-term haloperidol treatment of old rats. Neurosci 2003;122:717-725

Beal, M.F. Commentary - Alpha-synuclein and mitochondria: A tangled skein. Exp Neurol, in press

Beal M.F., Shults C.W. Effects of coenzyme Q10 in Huntington's disease and early Parkinson's disease. Biofactors 2003;18:153-161

Simon D.K., Lin M.T., Zheng L., Liu G.J., Ahn C.H., Kim L.M., Mauck W.M., Twu F., Beal M.F., Johns D.R. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's Disease. Neurobiol Aging 2004;25:71-81

Ulug A.M., Grunewald T., Lin M.T., Kamal A.K., Filippi C.G., Zimmerman R.D., Beal M.F. Diffusion tensor imaging in the diagnosis of primary lateral sclerosis. J Magn Reson Imaging 2004;19:34-39

Browne S.E., Roberts II L.J., Dennery P.A., Doctrow S.R., Beal M.F. Barlow C., Levine R.L.. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Rad Biol Med 2004, 36:938-942

Klivenyi P., Kiaei M., Gardian G., Calingasan N.Y., Beal M.F. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of ALS. J Neurochem 2004;88:576-582

Klivenyi P., Starkov A.A., Calingasan N.Y., Gardian G., Browne S.E., Yang L., Bubber P., Gibson G.E., Patel M.S., Beal M.F. Mice deficient in dihydrolipoamide dehydrogenase show incresed vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. J Neurochem 2004, in press

Lorenzl S., Albers D.S., Chirichigno J.W., Augood S.J., Beal M.F. Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. J Neurol Sci 2004; 218:39-45

Lorenzl S., Calingasan N., Yang L., Albers D.S., Shugama S., Gregorio J., Krell H. W., Chirichigno J., Joh T., Beal M.F. Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neuromolecular Med 2004, in press

Brownell A-L., Chen Y.I., Yu M., Wang X., Dedeoglu A., Beal M.F., Jenkins .G. 3-Nitroproionic acid induced neurotoxicity - assessed by ultra high resolution PET with comparison to MRI and MRS. J Neurochem 2004, in press

Klivenyi P., Calingasan N.Y., Stavrovskay I.G., Kristal B.S., Yang L., Petri S., Wieringa B., Beal M.F. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol Dis 2004, in press

Starkov A.A., Fiskum G., Chinopoulos C., Lorenzo B.J., Browne S.E. Patel M.S., Beal M.F Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Biol Cem 2004' submitted

Li F., Calingasan N.Y., Fangmin Y., Mauck W.M., Almeida C. G., Takahashi R. H., Carlson G. A., Beal M.F., Lin M.T., Gouras G.K. Increased beta-amyloid levels and plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem 2004, in press